Phase 2 final data on PV-10 for metastatic melanoma by Provectus Pharmaceuticals, Inc. (OTCBB: PVCT) will be presented at the second European PostASCO Melanoma Meeting 2012, Interdisciplinary Global Conference on Developing New Treatments for Melanoma. Sanjiv Agarwala, MD, principal investigator for the PV-10 Phase 2 trial, will present the data on June 22, 2012, in Munich, Germany. He is expected to present an analysis of the impact of PV-10 on progression-free survival, the suggested primary endpoint for the proposed Phase 3 protocol to qualify for Special Protocol Assessment with the Food and Drug Administration, says the company.